Skip to main content

Peer Review reports

From: A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

Original Submission
14 Sep 2016 Submitted Original manuscript
20 Sep 2016 Author responded Author comments - Xin Liu
Resubmission - Version 2
20 Sep 2016 Submitted Manuscript version 2
31 Oct 2016 Reviewed Reviewer Report - Russell Petty
12 Nov 2016 Reviewed Reviewer Report - Antoine Hollebecque
Resubmission - Version 3
Submitted Manuscript version 3
6 Jan 2017 Reviewed Reviewer Report - Takaaki Arigami
24 Jan 2017 Reviewed Reviewer Report - Reham Abdel-Wahab
10 Feb 2017 Author responded Author comments - Xin Liu
Resubmission - Version 4
10 Feb 2017 Submitted Manuscript version 4
21 Feb 2017 Author responded Author comments - Xin Liu
Resubmission - Version 5
21 Feb 2017 Submitted Manuscript version 5
Publishing
4 Mar 2017 Editorially accepted
14 Mar 2017 Article published 10.1186/s12885-017-3174-z

You can find further information about peer review here.

Back to article page